arrow
F

Fernando Salvador

solti cancer research group
H指数:15
被引数:989

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study

真实世界中HR+/HER2-转移性乳腺癌在接受一线CDK4/6抑制剂治疗后进展后的二线和三线无进展生存情况,按PAM50固有亚型分析:SOLTI-1801 CDK-PREDICT研究

2026-02-280
OAAI
Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial

PD1疗法在PD1高表达mRNA肿瘤中的疗效:SOLTI-1904 ACROPOLI II期试验中队列1和队列2的结果

2025-09-300
OAAI
Characterizing Immune Infiltration in Metastatic Hormone Receptor-Positive/HER2Negative Breast Cancer: A Comprehensive Translational Analysis from four SOLTI Clinical Trials
2024-05-020
PRE
MAF amplification licenses ERa through epigenetic remodelling to drive breast cancer metastasis
2023-11-091
OAAI
Efficacy of spartalizumab across multiple cancer types in patients with PD1-high mRNA expressing tumors (SOLTI1904 ACROPOLI)

spartalizumab在表达PD1-high mRNA的肿瘤患者中跨多种癌症类型的疗效 (SOLTI1904 ACROPOLI)

2023-10-010
OA
Gene expression profiling in tumors with and without tertiary lymphoid structures across cancer-types

跨癌症类型的具有和不具有三级淋巴样结构的肿瘤中的基因表达谱

2023-10-010
PRE
Tumor-infiltrating lymphocites and gene expression across multiple cancer-types: A translational analysis from the SOLTI-1904-ACROPOLI study

肿瘤浸润性淋巴细胞和多种癌症类型的基因表达: 来自SOLTI-1904-ACROPOLI研究的翻译分析

2023-10-010
PRE
SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA
2022-10-064
PRE
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial
2021-11-259
OAAI
SOLTI-1904: Efficacy of spartalizumab across multiple cancer-types in patients with PD1-high mRNA expressing tumors defined by a single and pre-specified cutoff (ACROPOLI)
2021-09-010
OAAI
Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy
2021-02-0318
OAAI
CHANGES IN T CELL CLONALITY IN AWARE-1 STUDY, A WINDOW-OF-OPPORTUNITY STUDY WITH ATEZOLIZUMAB AND THE ONCOLYTIC VIRUS PELAREOREP IN EARLY BREAST CANCER
2020-11-091
OAAI
Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer
2020-03-2720
OAAI